p> population: Costs trends by category presentation from
in the 12 months after diagnosis from 12pm-2pm PDT
1997 to 2002
808 Direct Medical Costs Associated with Oral; Tuesday, May
Constipation from Childhood to Early 20, 2008 from 4pm-
Adulthood: A Birth Cohort Study 5:30pm PDT;
Presentation from
4:30pm-4:45pm PDT
Pre-Clinical Data
T1876 Lubiprostone Activation of Cl- Poster; Tuesday,
Currents Does Not Involve Ca2+, cAMP, May 20, 2008 from
or PKA 8am-5pm PDT; Poster
presentation from
12pm-2pm PDT
T1877 ClC-2-Targeted siRNA Eliminates Poster; Tuesday,
Lubiprostone Activation of Cl- May 20, 2008 from
Currents in T84 Cells 8am-5pm PDT; Poster
presentation from
12pm-2pm PDT
T1081 Effect of Lubiprostone on Duodenal Poster; Tuesday,
Mucosal Bicarbonate Secretion May 20, 2008 from
8am-5pm PDT; Poster
presentation from
12pm-2pm PDT
844 Lubiprostone Reverses the Inhibitory Oral; Tuesday, May
Action of Morphine on Mucosal 20, 2008 from 4pm-
Secretion in the Human Jejunum 5:30pm PDT;
Presentation from
'/>"/>
SOURCE Takeda Pharmaceuticals North America, Inc.; SucampoPharmaceuticals, Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis2.
Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials3.
BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting4.
GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)5.
Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease6.
Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial7.
VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial8.
Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-110479.
Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial10.
NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.11.
Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy